Koch-Henriksen N - Search Results

1

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K. Ross C, et al. Ann Neurol. 2000 Nov;48(5):706-12. Ann Neurol. 2000. PMID: 11079533

2

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.

Koch-Henriksen N, Sørensen PS. Koch-Henriksen N, et al. Mult Scler. 2000 Jun;6(3):172-5. doi: 10.1177/135245850000600306. Mult Scler. 2000. PMID: 10871828 Clinical Trial.

3

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.

Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K; Danish Multiple Sclerosis Study Group. Sorensen PS, et al. Neurology. 2005 Jul 12;65(1):33-9. doi: 10.1212/01.WNL.0000166049.51502.6A. Epub 2005 May 11. Neurology. 2005. PMID: 15888603

4

CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis.

Sellebjerg F, Ross C, Koch-Henriksen N, Sørensen PS, Frederiksen JL, Bendtzen K, Sørensen TL. Sellebjerg F, et al. Mult Scler. 2005 Dec;11(6):641-5. doi: 10.1191/1352458505ms1217oa. Mult Scler. 2005. PMID: 16320722 Clinical Trial.

5

Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis.

Ross C, Clemmesen KM, Sørensen PS, Koch-Henriksen N, Bendtzen K. Ross C, et al. Mult Scler. 2006 Feb;12(1):39-46. doi: 10.1191/1352458506ms1272oa. Mult Scler. 2006. PMID: 16459718

6

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, Heltberg A, Kristensen O, Stenager E, Petersen T, Hansen T; Danish Multiple Sclerosis Group. Koch-Henriksen N, et al. Neurology. 2006 Apr 11;66(7):1056-60. doi: 10.1212/01.wnl.0000204018.52311.ec. Epub 2006 Mar 1. Neurology. 2006. PMID: 16510769 Clinical Trial.

7

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?

Sorensen PS, Koch-Henriksen N, Bendtzen K. Sorensen PS, et al. Mult Scler. 2007 Jun;13(5):616-21. doi: 10.1177/1352458506072344. Epub 2007 Feb 9. Mult Scler. 2007. PMID: 17548440 Clinical Trial.

8

Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?

Sorensen PS, Koch-Henriksen N, Flachs EM, Bendtzen K. Sorensen PS, et al. Mult Scler. 2008 Jul;14(6):837-42. doi: 10.1177/1352458508088942. Epub 2008 May 27. Mult Scler. 2008. PMID: 18505772 Clinical Trial.

9

Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.

Hesse D, Frederiksen JL, Koch-Henriksen N, Schreiber K, Stenager E, Heltberg A, Ravnborg M, Bendtzen K, Sellebjerg F, Sorensen PS. Hesse D, et al. Eur J Neurol. 2009 Jan;16(1):43-7. doi: 10.1111/j.1468-1331.2008.02336.x. Eur J Neurol. 2009. PMID: 19087149 Clinical Trial.

10

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM. Koch-Henriksen N, et al. Mult Scler. 2009 May;15(5):601-5. doi: 10.1177/1352458508101946. Epub 2009 Mar 19. Mult Scler. 2009. PMID: 19299439

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters